BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...therapies including a PD-1 blocker. Amgen’s closest competition, Mirati Therapeutics Inc....
...Vascular endothelial growth factor Lauren Martz sotorasib (AMG 510) MRTX849 Amgen Inc. Mirati Therapeutics Inc. KRAS...
BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...different ways may produce complementary effects.The companies will test the G12C mutation-selective inhibitor MRTX849 from Mirati Therapeutics Inc....
...SHPTP2; PTPN11) – Src homology protein tyrosine phosphatase 2SOS1 – Sons of sevenless homolog 1 Lauren Martz Mirati Therapeutics Inc. Amgen...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...Phase I testing to treat cancer. The most advanced K-Ras inhibitors in development, MRTX849 from Mirati Therapeutics Inc....
...lambrolizumab) ravidasvir (ASC16, PPI-668) Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) AL001 Boehringer Ingelheim GmbH AbbVie Inc. Eli Lilly and Co. Mirati Therapeutics Inc. Amgen...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

...inhibitor in Phase II testing; sitravatinib, a multi-kinase inhibitor to which BeiGene shares rights with Mirati Therapeutics Inc....
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...compromised immune systems, hired Chris LeMasters as COO, a new position. He was CBO at Mirati Therapeutics Inc....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...and co-chairman and CEO of Ping An Medical and Healthcare Management Co. Ltd. Cancer company Mirati Therapeutics Inc....
...for opthalmology at Novartis. Robin Sawka, BioCentury Staff Merck & Co. Inc. Ping An Healthcare and Technology Co. Ltd. Mirati Therapeutics Inc. Evox...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...its initial target. Oncogenuity is targeting a different K-Ras mutation than Amgen Inc. (NASDAQ:AMGN) and Mirati Therapeutics Inc....
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

...set of oncogenic targets recently cracked open by KRAS inhibitors from Amgen Inc. (NASDAQ:AMGN) and Mirati Therapeutics Inc....
BioCentury | Apr 9, 2020
Tools & Techniques

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

...protein function. A similar strategy is the basis for K-Ras inhibitors from Amgen Inc. (NASDAQ:AMGN), Mirati Therapeutics Inc....
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...CovX research unit of Pfizer Inc. (NYSE:PFE) in 2004-11 and also served as chairman of Mirati Therapeutics Inc....
Items per page:
1 - 10 of 304
BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...therapies including a PD-1 blocker. Amgen’s closest competition, Mirati Therapeutics Inc....
...Vascular endothelial growth factor Lauren Martz sotorasib (AMG 510) MRTX849 Amgen Inc. Mirati Therapeutics Inc. KRAS...
BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...different ways may produce complementary effects.The companies will test the G12C mutation-selective inhibitor MRTX849 from Mirati Therapeutics Inc....
...SHPTP2; PTPN11) – Src homology protein tyrosine phosphatase 2SOS1 – Sons of sevenless homolog 1 Lauren Martz Mirati Therapeutics Inc. Amgen...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...Phase I testing to treat cancer. The most advanced K-Ras inhibitors in development, MRTX849 from Mirati Therapeutics Inc....
...lambrolizumab) ravidasvir (ASC16, PPI-668) Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) AL001 Boehringer Ingelheim GmbH AbbVie Inc. Eli Lilly and Co. Mirati Therapeutics Inc. Amgen...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

...inhibitor in Phase II testing; sitravatinib, a multi-kinase inhibitor to which BeiGene shares rights with Mirati Therapeutics Inc....
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...compromised immune systems, hired Chris LeMasters as COO, a new position. He was CBO at Mirati Therapeutics Inc....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...and co-chairman and CEO of Ping An Medical and Healthcare Management Co. Ltd. Cancer company Mirati Therapeutics Inc....
...for opthalmology at Novartis. Robin Sawka, BioCentury Staff Merck & Co. Inc. Ping An Healthcare and Technology Co. Ltd. Mirati Therapeutics Inc. Evox...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...its initial target. Oncogenuity is targeting a different K-Ras mutation than Amgen Inc. (NASDAQ:AMGN) and Mirati Therapeutics Inc....
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

...set of oncogenic targets recently cracked open by KRAS inhibitors from Amgen Inc. (NASDAQ:AMGN) and Mirati Therapeutics Inc....
BioCentury | Apr 9, 2020
Tools & Techniques

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

...protein function. A similar strategy is the basis for K-Ras inhibitors from Amgen Inc. (NASDAQ:AMGN), Mirati Therapeutics Inc....
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...CovX research unit of Pfizer Inc. (NYSE:PFE) in 2004-11 and also served as chairman of Mirati Therapeutics Inc....
Items per page:
1 - 10 of 304